{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pevonedistat", "query": { "intervention": "pevonedistat" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pevonedistat&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-15T05:23:56.887Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04266795", "title": "A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2020-10-13", "completion_date": "2025-10-06", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 23, "location_summary": "Gilbert, Arizona • La Jolla, California • Orange, California + 20 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04266795" }, { "nct_id": "NCT03479268", "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Prolymphocytic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Richter Syndrome" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-04-27", "completion_date": "2026-11-05", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 2, "location_summary": "Duarte, California • Buffalo, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03479268" }, { "nct_id": "NCT03813147", "title": "Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Month to 21 Years" }, "enrollment_count": 12, "start_date": "2019-05-17", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03813147" }, { "nct_id": "NCT01814826", "title": "Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "MLN4924", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 64, "start_date": "2013-04-10", "completion_date": "2018-04-08", "has_results": true, "last_update_posted_date": "2020-03-03", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Stanford, California • Denver, Colorado + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01814826" }, { "nct_id": "NCT03862157", "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Eosinophilic Leukemia, Not Otherwise Specified", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Essential Thrombocythemia", "Myelodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloid Neoplasm", "Myeloproliferative Neoplasm", "Myeloproliferative Neoplasm, Unclassifiable", "Overt Primary Myelofibrosis", "Polycythemia Vera", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Prefibrotic/Early Primary Myelofibrosis" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-02-27", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03862157" }, { "nct_id": "NCT03770260", "title": "Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-02-10", "completion_date": "2023-07-06", "has_results": true, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Tampa, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03770260" }, { "nct_id": "NCT03330106", "title": "A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Neoplasm" ], "interventions": [ { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-11-15", "completion_date": "2021-06-21", "has_results": true, "last_update_posted_date": "2023-03-28", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 8, "location_summary": "Santa Monica, California • Tampa, Florida • Detroit, Michigan + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03330106" }, { "nct_id": "NCT00677170", "title": "Study of MLN4924 in Adult Patients With Nonhematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Nonhematologic Malignancies" ], "interventions": [ { "name": "MLN4924", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2008-04", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-07-16", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 3, "location_summary": "Atlanta, Georgia • San Antonio, Texas", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00677170" }, { "nct_id": "NCT00722488", "title": "Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies", "Multiple Myeloma", "Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "MLN4924", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2008-06", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2013-11-18", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Buffalo, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00722488" }, { "nct_id": "NCT03349281", "title": "Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Acute Lymphoblastic Leukemia", "Relapsed Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "PEG-asparaginase", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Julio Barredo, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "16 Years to 39 Years" }, "enrollment_count": 6, "start_date": "2019-03-25", "completion_date": "2022-10-12", "has_results": false, "last_update_posted_date": "2022-10-20", "last_synced_at": "2026-09-15T05:23:56.887Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03349281" } ] }